The American College of Chest Physicians (CHEST) has submitted formal comments to the U.S. Office of Management and Budget (OMB) on proposed updates to federal policies for research grants, cooperative agreements, and other financial assistance. CHEST said it supports reforms aimed at transparency and accountability, but warned that poorly calibrated rule changes could destabilize the research pipeline that turns discoveries into therapies.
At the center of the OMB proposal is a promise to ensure responsible use of funds, strengthen compliance with program requirements, prohibit unlawful discrimination, and reduce unnecessary administrative burden. CHEST agrees with these goals in principle, yet argues that several proposed mechanisms may shift decision-making away from evidence-driven scientific evaluation.
CHEST’s core concern is “scientific instability”—a risk that the organization says is not just a governance abstraction, but a direct threat to patient outcomes. In pulmonary, critical care, and sleep medicine, breakthroughs commonly depend on long-running projects rather than one-off experiments.
Many advances require a sustained sequence: basic laboratory work, preclinical validation, multi-phase clinical trials, regulatory review, and eventual integration into clinical practice. CHEST emphasizes that stable funding signals and predictable oversight help investigators preserve study designs, enrollment, data integrity, and long-term follow-up.
Interruptions can ripple through the entire evidence system. If clinical trials or longitudinal cohorts are disrupted, years of work can be rendered unusable, inflating both scientific waste and financial costs. The organization also notes that delays may expose research participants to avoidable risk and reduce the quality of evidence available to clinicians.
CHEST also argues that studying clinically meaningful subgroup differences—across the populations medicine serves—is essential for translating findings into real-world care. “Accountability” and “scientific excellence,” the group says, must be paired rather than traded off against one another.
To shape its response, CHEST framed recommendations around maintaining independent scientific and clinical expertise, supporting stable infrastructure for long-term investigation, encouraging collaboration across research institutions and health systems, and accelerating translation of results into practice.
Looking ahead, CHEST says it will continue engaging in the federal rulemaking process to protect public trust while safeguarding the research ecosystem. The organization’s message to policymakers is clear: reforms should reinforce rigorous science and responsible stewardship, not interrupt the generation of evidence that guides the care patients rely on.
Keywords: American College of Chest Physicians (CHEST), OMB, federal research policy, research grants, scientific accountability, clinical trials, evidence generation, pulmonary medicine, critical care, sleep medicine
Subject of Research: Federal policies governing research grants and cooperative agreements affecting medical research
Article Title: CHEST Submits Comments to OMB on Proposed Revisions to Federal Research Funding Policies
News Publication Date: 2026-07-13
Web References: https://www.chestnet.org/-/media/documents/advocacy/20260713chestombrulecomments.ashx
References: N/A
Image Credits: N/A
